PureTech Health (LON:PRTC) Stock Crosses Below Fifty Day Moving Average - Should You Sell?

Key Points

• PureTech Health plc saw its stock cross below the 50-day moving average of GBX 134.81, with recent trading lowest at GBX 127.40.
• The company has a market cap of £384.49 million, a P/E ratio of -5.25, and high liquidity ratios indicating a strong financial position.
• Insider Bharatt Chowrira purchased 167,739 shares at £1 ($0.01) each, reflecting confidence from corporate insiders who collectively own 15.93% of the stock.

PureTech Health plc (LON:PRTC - Get Free Report) passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of GBX 134.81 ($1.82) and traded as low as GBX 127.40 ($1.72). PureTech Health shares last traded at GBX 129.60 ($1.75), with a volume of 344,765 shares traded.

PureTech Health Trading Down 2.1%

The business has a 50-day simple moving average of GBX 134.41 and a two-hundred day simple moving average of GBX 133.97. The stock has a market cap of £393.50 million, a price-to-earnings ratio of -5.37 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51.

Insiders Place Their Bets

In other PureTech Health news, insider Bharatt Chowrira purchased 167,739 shares of the stock in a transaction on Thursday, July 3rd. The shares were purchased at an average price of GBX 1 ($0.01) per share, with a total value of £1,677.39 ($2,269.50). 15.93% of the stock is currently owned by company insiders.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.